Abstract P3-07-15: Prosigna® subtype correlation is a strong predictor of response to neoadjuvant chemotherapy (NAC) in early breast cancer (EBC) study

@inproceedings{Parrado2016AbstractPP,
  title={Abstract P3-07-15: Prosigna® subtype correlation is a strong predictor of response to neoadjuvant chemotherapy (NAC) in early breast cancer (EBC) study},
  author={Ramiro Parrado and Bego{\~n}a Jim{\'e}nez-Rodr{\'i}guez and Pedro S{\'a}nchez Rovira and M. {\'A}lvarez and Lu{\'i}s Vicioso and Ana I. Fern{\'a}ndez and Vanessa de Luque and Mar{\'i}a Jos{\'e} Lozano and E Villar and Irene Zarcos and Cristina Paula Ram{\'i}rez and Carlos Gonz{\'a}lez-Hermoso and Arthur Jeiranian and Naeem Dowidar and Carl Schaper and Wesley Buckingham and Sean Ferree and Nuria Ribelles and I. P{\'e}rez Rodrigo and Aleix Prat and Emilio Alba},
  year={2016}
}
Background: Prosigna9s ROR score was demonstrated as a strong predictor of response to NAC in a representative cohort of EBC patients including HR+/HER2- N0-N1 patients.1 Given that the ROR score is partially derived from the correlation of the tumor9s expression profile to that of the four prototypical intrinsic subtypes, we determined the relative strength of the association between each subtype correlation and the likelihood of response to NAC. Methods: We analyzed 294 FFPE breast cancer… CONTINUE READING